Related Experiment Video

Updated: May 22, 2026

Identification, Histological Characterization, and Dissection of Mouse Prostate Lobes for In Vitro 3D Spheroid Culture Models
08:43

Identification, Histological Characterization, and Dissection of Mouse Prostate Lobes for In Vitro 3D Spheroid Culture Models

Published on: September 18, 2018

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer

R Siobhan Darrington1, Victor M Campa, Marjorie M Walker

  • 1Department of Surgery and Cancer, Imperial College London, London, United Kingdom.

International Journal of Cancer
|April 28, 2012
PubMed

Insights

Glycogen synthase kinase (GSK-3) isoforms are upregulated in prostate cancer and linked to androgen receptor (AR) activity. Inhibiting GSK-3 may offer new therapeutic strategies, particularly when combined with AR antagonists for treating prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Glycogen synthase kinase (GSK-3) is implicated in various cancers, including prostate cancer.
  • GSK-3 inhibitors show promise in reducing prostate tumor cell growth, but the specific roles of its isoforms, GSK-3α and GSK-3β, remain unclear.
  • The interplay between GSK-3 isoforms and the androgen receptor (AR) in prostate cancer progression requires further investigation.

Purpose of the Study:

  • To compare the expression of GSK-3α and GSK-3β in prostate tumors.
  • To investigate the functional roles of GSK-3α and GSK-3β in prostate cancer cell lines.
  • To evaluate the therapeutic potential of targeting GSK-3, alone and in combination with AR antagonists.

Main Methods:

  • Quantitative analysis of GSK-3α and GSK-3β expression in prostate tumor samples.
  • Gene silencing techniques (siRNA) to inhibit GSK-3α and GSK-3β in 22Rv1 prostate cancer cells.
  • Assessment of AR transcriptional activity, Akt phosphorylation, and cell proliferation (colony formation assays).
  • Treatment with GSK-3 inhibitor (CHIR99021) and AR antagonists (bicalutamide, MDV3100).

Main Results:

  • Both GSK-3α and GSK-3β were upregulated in prostate tumors, with distinct correlations to Gleason scores and AR expression.
  • Silencing GSK-3α and GSK-3β reduced AR transcriptional activity, while only GSK-3β silencing affected Akt phosphorylation.
  • GSK-3 inhibition reduced prostate cancer cell growth in both hormone-dependent and independent conditions and enhanced the efficacy of AR antagonists.

Conclusions:

  • GSK-3 isoforms play significant roles in prostate cancer, influencing AR signaling and cell proliferation.
  • The GSK-3/AR signaling axis represents a critical pathway in prostate cancer.
  • Targeting GSK-3, especially with isoform-specific inhibitors in combination with AR antagonists, holds therapeutic promise for prostate cancer treatment.

More Related Videos

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death09:18

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death

Published on: December 27, 2016

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high affinity and are together...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...